Product Description
Mechanisms of Action: cGAS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant,Intramuscular,Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vitaflo International
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12624000125527 | P1 |
Completed |
Arthritis, Rheumatoid |
2025-05-06 |
2025-07-07 |
Patient Enrollment|Primary Completion Date|Treatments|Trial Status |